Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Triamcinolone Hexacetonide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 4/20 | 0.75 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.75 |
| ▸ | LMNA | P02545 | 5/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.75 |
| ▸ | PGR | P06401 | 4/20 | 0.75 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.75 |
| ▸ | MAPT | P10636 | 3/20 | 0.72 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.72 |
| ▸ | CNR1 | P21554 | 1/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.72 |
| ▸ | USP2 | O75604 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | AR | P10275 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.57 |
| ▸ | IKBKB | O14920 | 1/20 | 0.56 |
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triamcinolone Hexacetonide SCHEMBL6835644 | 1.00 | HIF1A (0.75) | HIF1ALMNACYP3A4NR3C1PGR | |
| Triamcinolone Hexacetonide SCHEMBL5485022 | 1.00 | HIF1A (0.75) | HIF1ALMNACYP3A4NR3C1PGR | |
| Triamcinolone Hexacetonide SCHEMBL21091792 | 1.00 | HIF1A (0.75) | HIF1ALMNACYP3A4NR3C1PGR | |
| SCHEMBL12087295 | 0.92 | HIF1A (0.84) | HIF1ALMNACYP3A4NR3C1PGR | |
| SCHEMBL19762242 | 0.91 | HIF1A (0.78) | HIF1ALMNACYP3A4NR3C1PGR | |
| SCHEMBL28971361 | 0.90 | HIF1A (0.87) | HIF1ALMNACYP3A4NR3C1PGR | |
| SCHEMBL11422147 | 0.90 | HIF1A (0.87) | HIF1ALMNACYP3A4NR3C1PGR | |
| SCHEMBL15975096 | 0.90 | HIF1A (0.87) | HIF1ALMNACYP3A4NR3C1PGR | |
| SCHEMBL14884636 | 0.90 | HIF1A (0.87) | HIF1ALMNACYP3A4NR3C1PGR | |
| SCHEMBL124165 | 0.90 | HIF1A (0.87) | HIF1ALMNACYP3A4NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8616 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725087-A1 | FAULT CURRENT MONITORING DEVICE AND METHOD | Siemens Aktiengesellschaft (DE) | 2026-04-15 | — | — | EP | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| EP-3820479-B1 | METHODS TO REDUCE COMPLICATIONS OF INTRA-ARTICULAR STEROID | TAIWAN LIPOSOME CO LTD (TW) | 2026-03-11 | — | — | EP | claimed |
| US-20260062541-A1 | METHOD FOR MANUFACTURING CROSSLINKED HYALURONIC ACID GEL CONTAINING TRIAMCINOLONE AND CROSSLINKED HYALURONIC ACID GEL | SCIVISION BIOTECH INC. (TW) | 2026-03-05 | — | — | US | claimed |
| EP-4702972-A1 | METHOD FOR MANUFACTURING CROSSLINKED HYALURONIC ACID GEL CONTAINING TRIAMCINOLONE AND CROSSLINKED HYALURONIC ACID GEL | Scivision Biotech Inc. (TW) | 2026-03-04 | — | — | EP | claimed |
| EP-3622820-B1 | STABLE HYALURONAN/STEROID FORMULATION | GENZYME CORP (US) | 2026-02-18 | — | — | EP | claimed |
| US-20250255870-A1 | METHODS FOR TREATING HAIR LOSS AND NAIL BRITTLENESS, FRAGILITY, OR PITTING | CHEMISTRY RX | 2025-08-14 | — | — | US | claimed |
| US-20250242092-A1 | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS | SIO2 MEDICAL PRODUCTS INC (US) | 2025-07-31 | — | — | US | claimed |
| EP-4590288-A1 | A PHARMACEUTICAL COMPOSITION FOR TOPICAL APPLICATION AND USE THEREOF IN THE TREATMENT OF HEMANGIOMAS IN CHILDREN | Uniwersytet Medyczny W Lodzi (PL) | 2025-07-30 | — | — | EP | claimed |
| WO-2025096949-A1 | LIPOSOMAL COMPOSITION OF INTRA-ARTICULAR CORTICOSTEROID FOR PAIN CONTROL | TAIWAN LIPOSOME COMPANY, LTD. (CN) | 2025-05-08 | — | — | WO | claimed |
| CN-1137748-A | Gas used as local and subcutaneous transmission carrier and microspheres filled with gas precursor | IMARX PHARMACEUTICAL CORP (US) | 1996-12-11 | — | — | CN | claimed |
| EP-0740528-A1 | GAS MICROSPHERES FOR TOPICAL AND SUBCUTANEOUS APPLICATION | IMARX PHARMACEUTICAL CORP. (US) | 1996-11-06 | — | — | EP | claimed |
| US-5543417-A | 5 Alpha-reductase inhibitor and at least one of an antibacterial agent, a keratolytic agent or an anti-inflammatory agent | MERCK & CO., INC. (US) | 1996-08-06 | — | — | US | claimed |
| WO-1996012487-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| WO-1996012817-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| WO-1995015118-A1 | GAS MICROSPHERES FOR TOPICAL AND SUBCUTANEOUS APPLICATION | IMARX PHARMACEUTICAL CORP. (US) | 1995-06-08 | — | — | WO | claimed |
| EP-0496520-A1 | Novel bone acting agents | MERCK & CO. INC. (US) | 1992-07-29 | — | — | EP | claimed |
| US-4970206-A | TRANSDERMAL DRUG DELIVERY | MERCK & CO., INC. (US) | 1990-11-13 | — | — | US | claimed |
| US-4478818-A | Ocular preparation housing steroid in two different therapeutic forms | ALZA CORPORATION (US) | 1984-10-23 | — | — | US | claimed |
| US-4279900-A | ANTIINFLAMMATORY | INTREX RESEARCH CORPORATION (US) | 1981-07-21 | — | — | US | claimed |